Inferring Genetic Variation and Discovering Associations with Phenotypes

BMI/CS 776

www.biostat.wisc.edu/bmi776/

Spring 2021

Daifeng Wang

daifeng.wang@wisc.edu

Outline

- Variation detection
  - Array technologies
  - Whole-genome sequencing
- GWAS and QTL basics
  - Testing SNPs for association
  - Correcting for multiple-testing

Variation detecting technologies

- Array-based technologies
  - Relies on hybridization of sample DNA to pre-specified probes
  - Each probe is chosen to measure a single possible variant: SNP, CNV, etc.



Affymetrix SNP chip

- Sequencing-based technologies
  - Whole-genome shotgun sequence, usually at low coverage (e.g., 4-8x)
  - Align reads to reference genome: mismatches, indels, etc. indicate variations
  - Long read sequencing


Illumina HiSeq sequencer

Array-based technologies

- Currently two major players
- Affymetrix Genome-Wide Human SNP Arrays
  - Used for HapMap project, Navigenics service
- Illumina BeadChips
  - Used by 23andMe, deCODEme services

Affymetrix SNP arrays

- Probes for ~900K SNPs
- Another ~900K probes for CNV analysis
- Differential hybridization – one probe for each possible SNP allele



Illumina BeadChips

- OmniExpress+
  - ~900K SNPs (700K fixed, 200 custom)
- Array with probes immediately adjacent to variant location
- Single base extension (like sequencing) to determine base at variant location



The Infinium HD Assay protocol features single-tube sample preparation and whole-genome amplification without PCR or ligation steps, significantly reducing labor and sample-handling errors.

Illumina

Sequencing-based genotyping

compute $\underset{genotype}{\text{argmax}}\ P(genotype \mid reads, reference)$ for each genomic position



Long read sequencing

- Pacific Biosciences SMRT
- MinION nanopore
- Illumina TruSeq Synthetic

De novo assembly of two Swedish genomes reveals missing segments from the human GRCh38 reference and improves variant calling of population-scale sequencing data

Adam Ameur, Huiwen Che, Marcel Martin, Ignas Bunikis, Johan Dahlberg, Ida Höijer, Susana Häggqvist, Francesco Vezzi, Jessica Nordlund, Pall Olason, Lars Feuk, Ulf Gyllensten

doi: https://doi.org/10.1101/267062

– "over 10 Mb of sequences absent from the human GRCh38 reference in each individual"

GWAS jargon

Locus - genetic position on a chromosome, and a single base pair position in the context of SNPs

SNP - a locus (single base pair) that exhibits variation (polymorphism) in a population

Allele (in the context of SNPs) - the alternative forms of a nucleotide at a particular locus

Genotype - the pair of alleles at a locus, one paternal and one maternal

Heterozygous - the two alleles differ at a locus

Homozygous - the two alleles are identical at a locus

Genotyped SNP - we have observed the genotype at a particular SNP, e.g. because the SNP is among the 1 million on the SNP array we used

Ungenotyped SNP - we have not observed the genotype at a particular locus

Causal SNP - a SNP that directly affects the phenotype, e.g. a mutation changes the amino acid sequence of a protein and changes the protein's function in a way that directly affects a biological process

Haplotype - a group of SNPs that are inherited jointly from a parent

Linkage disequilibrium - alleles at multiple loci that exhibit a dependence (nonrandom association)

Compiled from http://www.nature.com/scitable/definition/allele-48 http://www.nature.com/scitable/definition/genotype-234 http://www.nature.com/scitable/definition/haplotype-142 http://www.nature.com/scitable/definition/snp-295 https://en.wikipedia.org/wiki/Allele http://www.nature.com/nrg/journal/v9/n6/full/nrg2361.html https://www.snpedia.com/index.php/Glossary

GWAS data

Individual	Genotype at Position 1	Genotype at Position 2	Genotype at Position 3	…	Genotype at Position *M*	Disease?
1	CC	AG	GG		AA	N
2	AC	AA	TG		AA	Y
3	AA	AA	GG		AT	Y
…						
N	AC	AA	TT		AT	N

- *N* individuals genotyped at *M* positions
- Disease status (or other phenotype) is measured for each individual

GWAS task

- *Given*: genotypes and phenotypes of individuals in a population
- *Do*: identify which genomic positions are associated with a given phenotype

Can we identify causal SNPs?

- Typically only genotype at 1 million sites
- Humans vary at ~100 million sites
- Unlikely that an associated SNP is causal
- **Tag SNPs**: associated SNPs "tag" blocks of the genome that contain the causal variant



Direct and indirect associations



SNP imputation

- Estimate the ungenotyped SNPs using reference haplotypes

1000 Genomes

SNP array



Nielsen *Nature* 2010

Genotype imputation

- Evaluate the evidence for association at genetic markers that are not directly genotyped
- Increases power of genome-wide association scans
- Useful for combining data from studies that rely on different genotyping platforms



***Genotype imputation.**
Li Y, et al, Annu Rev Genomics Hum Genet. 2009

A pipeline for genotype imputation



Wang et al., Science, 2018

Basics of association testing

- Test each site individually for association with a statistical test
  - each site is assigned a *p*-value for the null hypothesis that the site is **not** associated with the phenotype
- Correct for the fact that we are testing **multiple hypotheses**

Basic genotype test

- Assuming binary phenotype (e.g., disease status)
- Test for significant association with Pearson's Chi-squared test or Fisher's Exact Test

genotype

	AA	AT	TT
Disease	40	30	30
No disease	70	20	10

phenotype

Chi-squared test *p*-value = 4.1e-5 (2 degrees of freedom)
Fisher's Exact Test *p*-value = 3.4e-5

Armitage (trend) test

- Can gain more statistical power if we can assume that probability of trait is linear in the number of one of the alleles



Balding *Nature Reviews Genetics* 2006

Trend test example

genotype

phenotype

	AA	AT	TT
Disease	40	30	30
No disease	70	20	10

Disease proportion	0.36	0.60	0.75

Trend in Proportions test *p*-value = 8.1e-6

(note that this is a smaller *p*-value than from the basic genotype test)

GWAS Versus QTL

- Both associate genotype with phenotype
- GWAS pertains to discrete phenotypes
  - For example, disease status is binary
- QTL pertains to quantitative (continuous) phenotypes
  - Height
  - Gene expression
  - Splicing events
  - Metabolite abundance

Expression QTL (eQTL)

- traits are expression levels of various genes

- Merge expression from all studies
- Filtered out the very lowly-expressed genes by minimum of 50 samples having an FPKM value of at least 0.1

- Quantile normalization



RA Irizarry (web post)

- Inverse quantile normalization



- PEER calculations

Stegle et al, (2010)



A pipeline for eQTLs

- MAF>=0.01
- R2>0.3
- Hardy-Weinberg Equilibrium $p<1x10^{-6}$



- 65 covariates
  - Top 3 genotyping principal components
  - Probabilistic Estimation of Expression Residuals (PEER) factors
  - Genotyping array platform
  - Gender
  - Disease status



Wang et al., Science, 2018

Challenges of association studies (e.g., GWAS)

- Population structure
- Interacting variants
- Multiple testing
- Interpreting hits

Population structure issues

- If certain populations disproportionally represent cases or controls, then spurious associations may be identified

ACTCTACGTAC
ACTCTACGTAC

AA

Individual with genotype 1

ACTCTTCGTAC
ACTCTTCGTAC

TT

Individual with genotype 2

One SNP for N = 40 individuals



Balding *Nature Reviews Genetics* 2006

Interacting variants

- Most traits are *complex*: not the result of a single gene or genomic position
- Ideally, we'd like to test *subsets* of variants for associations with traits
  - But there are a *huge* number of subsets!
  - Multiple testing correction will likely result in zero association calls
- Area of research
  - Only test carefully selected subsets
  - Bayesian version: put prior on subsets

Multiple testing

- In the genome-age, we have the ability to perform large numbers of statistical tests simultaneously
  - SNP associations (~1 million)
  - Gene differential expression tests (~ 20 thousand)
- Do traditional *p*-value thresholds apply in these cases?

Expression in BRCA1 and BRCA2 Mutation-Positive Tumors



Hedenfalk et al., *New England Journal of Medicine* 344:539-548, 2001.

- 7 patients with BRCA1 mutation-positive tumors vs. 7 patients with BRCA2 mutation-positive tumors
- 5631 genes assayed

Expression in BRCA1 and BRCA2 Mutation-Positive Tumors



- Key question: which genes are differentially expressed in these two sets of tumors?
- Methodology: for each gene, use a statistical test to assess the hypothesis that the expression levels differ in the two sets

Hypothesis testing

- Consider two competing hypotheses for a given gene
  - *null hypothesis*: the expression levels in the first set come from the same distribution as the levels in the second set
  - *alternative hypothesis*: they come from different distributions

- First calculate a test statistic for these measurements, and then determine its *p*-value

- ***p*-value**: the probability of observing a test statistic that is as extreme or more extreme than the one we have, assuming the null hypothesis is true

Calculating a *p*-value

1. Calculate test statistic (e.g. T statistic)

BRAC2   BRAC1

$$T = \frac{\bar{x}_1 - \bar{x}_2}{\sqrt{\frac{s_1^2}{n_1} + \frac{s_2^2}{n_2}}}$$

where $\bar{x}_j = \frac{1}{n_j}\sum_{i=1}^{n_j} x_{ij}$

$$s_j^2 = \frac{1}{n_j - 1}\sum_{i=1}^{n_j}(x_{ij} - \bar{x}_j)^2$$

2. See how much mass in null distribution with value this extreme or more



If test statistic is here, $p = 0.034$

Multiple testing problem

- If we're testing one gene, the *p*-value is a useful measure of whether the variation of the gene's expression across two groups is significant
- Suppose that most genes are not differentially expressed
- If we're testing 5000 genes that don't have a significant change in their expression (i.e. the null hypothesis holds), we'd still expect about 250 of them to have *p*-values ≤ 0.05
- Can think of *p*-value as the *false positive rate* over null genes

Family-wise error rate

- One way to deal with the multiple testing problem is to control the probability of rejecting **at least one** null hypothesis when all genes are null
- This is the *family-wise error rate* (FWER)
- Suppose you tested 5000 null genes and predicted that all genes with *p*-values ≤ 0.05 were differentially expressed

$$FWER = 1 - (1 - 0.05)^{5000} \approx 1$$

  - you are guaranteed to be wrong at least once!
  - above assumes tests are independent

Bonferroni correction

- Simplest approach
- Choose a *p*-value threshold β such that the FWER is $\leq \alpha$

$$\alpha = 1 - (1 - \beta)^g$$

- where *g* is the number of genes (tests)

$$\text{for } \beta g << 1, \quad \beta \approx \frac{\alpha}{g}$$

- For g=5000 and α=0.05 we set a *p*-value threshold of β=1e-5

Loss of power with FWER

- FWER, and Bonferroni in particular, reduce our power to reject null hypotheses
  - As *g* gets large, *p*-value threshold gets very small
- For expression analysis, FWER and false positive rate are not really the primary concern
  - We can live with false positives
  - We just don't want too many of them relative to the total number of genes called significant

The False Discovery Rate

[Benjamini & Hochberg '95; Storey & Tibshirani '02]

gene	*p*-value	rank
C	0.0001	1
F	0.001	2
G	0.016	3
J	0.019	4
I	0.030	5
B	0.052	6
A	0.10	7
D	0.35	8
H	0.51	9
E	0.70	10

- Suppose we pick a threshold, and call genes above this threshold "significant"
- The *false discovery rate* is the expected fraction of these that are mistakenly called significant (i.e. are truly null)

The False Discovery Rate

false positives (false discoveries)

	Called significant	Called not significant	Total
Null true	F	$m_0 - F$	m_0
Alternative true	T	$m_1 - T$	m_1
Total	S	$m - S$	m

Storey & Tibshirani *PNAS* 100(16), 2002

total significant at threshold

true positives

features (genes)

The False Discovery Rate

gene	*p*-value	rank
C	0.0001	1
F	0.001	2
G	0.016	3
J	0.019	4
I	0.030	5
B	0.052	6
A	0.10	7
D	0.35	8
H	0.51	9
E	0.70	10

t

p-value threshold

$$F(t) = \#\{\text{null } p_i \le t; i = 1 \ldots m\}$$

genes

$$S(t) = \#\{p_i \le t; i = 1 \ldots m\}$$

$$FDR(t) = E\left[\frac{F(t)}{S(t)}\right] \approx \frac{E[F(t)]}{E[S(t)]}$$

The False Discovery Rate

- To compute the FDR for a threshold *t*, we need to estimate *E*[*F*(*t*)] and *E*[*S*(*t*)]

$$FDR(t) = E\left[\frac{F(t)}{S(t)}\right] \approx \frac{E[F(t)]}{E[S(t)]}$$

estimate by the observed *S*(*t*)

$$S(t) = \#\{p_i \le t; i = 1 \ldots m\}$$

$$F(t) = \#\{\text{null } p_i \le t; i = 1 \ldots m\}$$

- So how can we estimate *E*[*F*(*t*)]?

Estimating E[F(t)]

- Two approaches we'll consider
  - Benjamini-Hochberg (BH)
  - Storey-Tibshirani (q-value)

- Different assumptions about null features (m_0)

Benjamini-Hochberg

- Suppose the fraction of genes that are truly null is very close to 1 so $m_0 \approx m$
- Then

$$E[F(t)] = E[\#\{\text{null } p_i \le t; i = 1 \ldots m\}] \approx mt$$

- Because *p*-values are uniformly distributed over [0,1] under the null model
- Suppose we choose a threshold *t* and observe that *S*(*t*) = *k*

$$FDR(t) \approx \frac{E[F(t)]}{S(t)} = \frac{mt}{k}$$

Benjamini-Hochberg

- Suppose we want FDR ≤ α
- Observation:

$$FDR(t) \leq \alpha$$

$$\frac{mt}{k} \leq \alpha$$

$$t \leq \frac{k}{m}\alpha$$

Benjamini-Hochberg

- Algorithm to obtain FDR ≤ α
- Sort the *p*-values of the genes so that they are in increasing order

$$P_{(1)} \leq P_{(2)} \ldots \leq P_{(m)}$$

- Select the largest *k* such that

$$P_{(k)} \leq \frac{k}{m} \alpha$$

- where we use $P_{(k)}$ as the *p*-value threshold *t*

What fraction of the genes are truly null?

- Consider the *p*-value histogram from Hedenfalk et al.
  - includes both null and alternative genes
  - but we expect null *p*-values to be uniformly distributed



expected histogram if all genes were null

estimated proportion of null *p*-values

actual proportion of null *p*-values

$$\pi_0 = \frac{m_0}{m}$$

$$\hat{\pi}_0(\lambda) = \frac{\#\{p_i > \lambda; i = 1 \ldots m\}}{m(1-\lambda)}$$

Storey & Tibshirani *PNAS* 100(16), 2002

Storey & Tibshirani approach

estimated proportion of null *p*-values

genes

$$FDR(t) \approx \frac{\hat{\pi}_0 \times m \times t}{\#\{p_i \le t\}}$$

p-value threshold

gene	*p*-value	rank	*q*-value
C	0.0001	1	0.0010
F	0.001	2	0.0050
G	0.016	3	0.0475
J	0.019	4	0.0475
I	0.030	5	0.0600
B	0.052	6	0.0867
A	0.10	7	0.1430
D	0.35	8	0.4380
H	0.51	9	0.5670
E	0.70	10	0.7000

t

$$\hat{q}(p_i) = \min_{t \ge p_i} FDR(t)$$

pick minimum FDR for all greater thresholds

q-value example for gene J

$m = 20$ $\quad t = 0.019$

$\hat{\pi}_0 = 0.5$ $\quad \#\{p_i \le t\} = 4$

$$FDR(t) \approx \frac{\hat{\pi}_0 \times m \times t}{\#\{p_i \le t\}}$$

$$= \frac{0.5 \times 20 \times 0.019}{4} = 0.0475$$

gene	*p*-value	rank	*q*-value
C	0.0001	1	0.0010
F	0.001	2	0.0050
G	0.016	3	0.0475
J	0.019	4	0.0475
I	0.030	5	0.0600
B	0.052	6	0.0867
A	0.10	7	0.1430
D	0.35	8	0.4380
H	0.51	9	0.5670
E	0.70	10	0.7000

t

$$\hat{q}(p_i) = \min_{t \ge p_i} FDR(t)$$

In this case, already have minimum FDR for all greater thresholds

q-values vs. *p*-values for Hedenfalk et al.



Storey & Tibshirani *PNAS* 100(16), 2002

FDR summary

- In many high-throughput experiments, we want to know what is different across two sets of conditions/individuals (e.g. which genes are differentially expressed)
- Because of the multiple testing problem, *p*-values may not be so informative in such cases
- FDR, however, tells us which fraction of significant features are likely to be null
- *q*-values based on the FDR can be readily computed from *p*-values (see Storey's R package qvalue)